Skip to main contentSkip to navigationSkip to search

Press release

Camurus Annual Report for 2016 released

30 March 2017 | Regulatory

Lund — 30 March 2017 —  Camurus AB (Nasdaq Stockholm: CAMX) today announces that the Annual Report for 2016 now is available at the company’s website:

For more information:
Fredrik Tiberg, President & CEO 
Tel. +46 (0)46 286 46 92   

Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92

About Camurus
Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit

TypeError: Cannot read properties of undefined (reading 'url')